Author

A. E. Oro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1

Frequent Co-Authors

S. Gaddam· 2 shared A. Bruckner· 1 shared A. Christiano· 1 shared A. Cramer· 1 shared A. K. Rustgi· 1 shared A. Pappalardo· 1 shared A. R. Jussila· 1 shared A. Rami· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Gaddam

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy

Y. Zhang, D. Karagiannis, H. Liu, M. Lin, Y. Fang, M. Jiang, X. Chen, S. Suresh, H. Huang, J. She, F. Shi, P. Yang, W. El-Rifai, A. Zaika, A. E. Oro, , J. Que

This study shows that p63 regulates the balance between squamous and neuroendocrine cell fates in esophageal development and cancer by modulating epigenetic mechanisms.

bioRxiv · Sep 9, 2023Cell Biology

Acquisition of drug resistance in basal cell nevus syndrome tumors through basal to squamous cell carcinoma transition

A. R. Jussila, D. Haensel, S. Gaddam, A. E. Oro

The paper identifies PCYT2, ETNK1, and the phosphatidylethanolamine biosynthetic pathway as genetic suppressors of drug resistance in Gorlin syndrome tumors through basal to squamous cell carcinoma transition.

bioRxiv · Jul 26, 2023Cancer Biology

A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa

G. Neumayer, J. Torkelson, S. Li, K. McCarthy, H. Zhen, M. Vangipuram, J. Jackow, A. Rami, C. Hansen, Z. Guo, S. Gaddam, A. Pappalardo, L. Li, A. Cramer, K. Roy, , A. E. Oro

This paper develops a scalable, GMP-compatible cell therapy for Dystrophic Epidermolysis Bullosa using CRISPR-corrected iPS cells to generate functional skin grafts.

bioRxiv · Feb 28, 2023 · PreprintBioengineering